β¨ Medicines and Tax Notices
NEW ZEALAND GAZETTE, No. 61
12 JUNE 2014
Schedule
Product: Celostea
Active Ingredient: Celecoxib 100mg
Dosage Form: Capsule
New Zealand Sponsor: Mylan New Zealand Limited
Manufacturer: Mylan Pharmaceuticals Inc, West Virginia, United States of America
Product: Celostea
Active Ingredient: Celecoxib 200mg
Dosage Form: Capsule
New Zealand Sponsor: Mylan New Zealand Limited
Manufacturer: Mylan Pharmaceuticals Inc, West Virginia, United States of America
Product: Emend
Active Ingredient: Aprepitant 165mg
Dosage Form: Capsule
New Zealand Sponsor: Merck Sharp & Dohme (New Zealand) Limited
Manufacturer: Alkermes Pharma Ireland Limited, County Westmeath, Ireland
Product: Revolade
Active Ingredient: Eltrombopag olamine 95.7mg equivalent to Eltrombopag 75mg
Dosage Form: Film coated tablet
New Zealand Sponsor: GlaxoSmithKline (NZ) Limited
Manufacturer: Glaxo Operations UK Limited (t/a Glaxo Wellcome Operations), Hertfordshire, United Kingdom
Dated this 6th day of June 2014.
STEWART JESSAMINE, Group Manager, Medsafe, Ministry of Health (pursuant to delegation given by the Minister of Health on 11 September 2013).
go3556
Consent to the Distribution of New Medicines
Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new medicines which were referred to the Minister of Health under the provisions of section 24(5) of the Act and are set out in the Schedule hereto:
Schedule
Product: Revolade
Active Ingredient: Eltrombopag olamine 31.9mg equivalent to Eltrombopag 25mg
Dosage Form: Film coated tablet
New Zealand Sponsor: GlaxoSmithKline (NZ) Limited
Manufacturer: Glaxo Operations UK Limited (t/a Glaxo Wellcome Operations), Hertfordshire, United Kingdom
Product: Revolade
Active Ingredient: Eltrombopag olamine 63.8mg equivalent to Eltrombopag 50mg
Dosage Form: Film coated tablet
New Zealand Sponsor: GlaxoSmithKline (NZ) Limited
Manufacturer: Glaxo Operations UK Limited (t/a Glaxo Wellcome Operations), Hertfordshire, United Kingdom
Dated this 6th day of June 2014.
STEWART JESSAMINE, Group Manager, Medsafe, Ministry of Health (pursuant to delegation given by the Minister of Health on 11 September 2013).
go3557
Inland Revenue
Tax Administration Act 1994
Notice of Withdrawal of Product Ruling BR Prd 12/05
-
This is a notice of withdrawal of a product ruling under section 91FJ of the Tax Administration Act 1994.
-
Product Ruling BR Prd 12/05 is withdrawn on Wednesday 11 June 2014 to allow a replacement ruling to be issued.
-
Product Ruling BR Prd 12/05 applied from 1 October 2012 to 1 October 2015.
-
It is anticipated that the replacement ruling will be issued on the publication of this notice in the New Zealand Gazette and that notice of the making of a replacement ruling will be published in the New Zealand Gazette on Thursday 19 June 2014.
Dated this 9th day of June 2014.
DINESH GUPTA, Manager, Taxpayer Rulings, Office of the Chief Tax Counsel, Inland Revenue.
go3621
Next Page →
β¨ LLM interpretation of page content
π₯ Consent to the Distribution of New Medicines
π₯ Health & Social Welfare6 June 2014
Medicines Act 1981, New Medicines, Distribution, Celostea, Emend, Revolade
- STEWART JESSAMINE, Group Manager, Medsafe, Ministry of Health
π₯ Consent to the Distribution of New Medicines
π₯ Health & Social Welfare6 June 2014
Medicines Act 1981, New Medicines, Distribution, Revolade
- STEWART JESSAMINE, Group Manager, Medsafe, Ministry of Health
π° Notice of Withdrawal of Product Ruling BR Prd 12/05
π° Finance & Revenue9 June 2014
Tax Administration Act 1994, Product Ruling, Withdrawal
- DINESH GUPTA, Manager, Taxpayer Rulings, Office of the Chief Tax Counsel, Inland Revenue
NZ Gazette 2014, No 61